President Donald Trump’s team is rejecting former President Biden's plan to cover weight loss drugs like Wegovy and Zepbound for older Americans through Medicare. The Centers for Medicare and Medicaid ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling nasty), or is at least thinking about it. These meds—which include Ozempic, ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Dr. Michael Greger is famous for several books including “How Not to Die,” and for his website nutritionfacts.org. He ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.